Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
A multifaceted tie-up effectively gives Beigene a net $1.5bn fund-raising and several Amgen drugs to sell locally.
Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
Like AMG 510, MRTX849 yields partial responses in some lung and colorectal tumours, but investors could have expected better.
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
Questions about clinical data aside, Imfinzi and tremelimumab could be filed for first-line lung cancer by the end of the year.
The Checkmate-9LA trial of Opdivo plus Yervoy yesterday read out positively for overall survival.
Tucatinib yields a positive result in breast cancer, vindicating Seattle Genetics’ acquisition of its originator.